Sincalide Biological Activity Application

Sinapultide - Windtree Therapeutics

Alternative Names: Aerosolized KL4 surfactant; AEROSURF; ATI-01; ATI-02; DSC-104; DSC-105; KL-4 lung surfactant; KL4 pulmonary surfactant; KL4 surfactant; Lucinactant; Surfaxin; Surfaxin LS

Latest Information Update: 23 Nov 2023

At a glance

• Originator The Scripps Research Institute
• Developer Discovery Laboratories; University of Pennsylvania; Windtree Therapeutics
• Class Amino acids; Anti-inflammatories; Antiasthmatics; Peptides; Surfactants
• Mechanism of Action Cell membrane permeability enhancers
• Orphan Drug Status Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Yes - Bronchopulmonary dysplasia; Acute lung injury; Adult respiratory distress syndrome; Cystic fibrosis; Neonatal respiratory distress syndrome; Meconium aspiration syndrome
• New Molecular Entity Yes
• Available For Licensing Yes

Highest Development Phases

• Phase II Neonatal respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
• No development reported Acute lung injury; Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Chronic obstructive pulmonary disease; Cystic fibrosis; Lung disorders; Reperfusion injury
• Discontinued Asthma; Meconium aspiration syndrome; Otitis media; Respiratory insufficiency; Rhinitis; Sinusitis

Most Recent Events

• 16 Nov 2023 Windtree Therapeutics has patent protection for SERCA2a activator class of drug candidates in the EU and USA
• 27 Apr 2022 Windtree Therapeutics has patent protection in USA and Europe
• 22 Mar 2022 Adverse events data from a phase II trial in SARS-COV-2 acute respiratory disease released by Windtree Therapeutics